Clinical Trial Update: Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Daratumumab, Pomalidomide, and Dexamethasone (DPd) for relapsed/refractory light chain (AL) amyloidosis in patients previously exposed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Amyloid, AL Amyloidosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING